**Prognostic Association between Common Laboratory Tests and Overall Survival in Elderly Men with De Novo Metastatic Castration Sensitive Prostate Cancer: A Population-Based Study in Canada**

Christopher J. D. Wallis 1,*, Bobby Shayegan 2, Scott C. Morgan 3, Robert J. Hamilton 4, Ilias Cagiannos 5, Naveen S. Basappa 5, Cristiano Ferrario 6, Geoffrey T. Gotto 7, Ricardo Fernandes 8, Soumyajit Roy 9, Krista L. Noonan 10, Tamim Niazi 11, Sebastien J. Hotte 12, Fred Saad 13*, Huong Hew 14, Katherine F. Y. Chan 14*, Laura Park-Wyllie 14 and Shawn Malone 3

1 Vanderbilt University Medical Center, Department of Urologic Surgery, Nashville, TN 37232-2765, USA
2 St. Joseph’s Healthcare, McMaster University, Hamilton, ON L8N 4A6, Canada; shayeb@mcmaster.ca
3 The Ottawa Hospital, University of Ottawa, Ottawa, ON K1H 8L6, Canada; smorgan@toh.ca (S.C.M.); icagiannos@toh.ca (I.C.); SMalone@toh.ca (S.M.)
4 Princess Margaret Cancer Centre, University of Toronto, Toronto, ON M5G 2M9, Canada; rob.hamilton@uhn.ca
5 Cross Cancer Institute, University of Alberta, Edmonton, AB T6G 1Z2, Canada; naven.basappa@albertahealthservices.ca
6 Segal Cancer Centre, Jewish General Hospital, McGill University, Quebec, QC H3T 1E2, Canada; cristiano.ferrario@mcgill.ca
7 Southern Alberta Institute of Urology, University of Calgary, Calgary, AB T2V 1P9, Canada; drgotto@gmail.com
8 London Regional Cancer Program, London, ON N6A 5W9, Canada; ricardo.fernandes@lhsc.on.ca
9 Radiation Oncology, Rush University Cancer Center, Chicago, IL 60612, USA; soumyajitroy8@gmail.com
10 BC Cancer Agency, University of British Columbia, Surrey, BC V5Z 4E6, Canada; knoonan2@bccancer.bc.ca
11 Jewish General Hospital, McGill University, Quebec, QC H3T 1E2, Canada; tniazi@jgh.mcgill.ca
12 Juravinski Cancer Centre, McMaster University, Hamilton, ON L8V 5C2, Canada; hotte@hhsc.ca
13 Centre Hospitalier de l’Université de Montréal, University of Montreal, Montréal, QC H2X 3E4, Canada; fredsaad@videotron.ca
14 Janssen Inc., Toronto, ON M3C 1L9, Canada; hzew@its.jnj.com (H.H.); kchan@its.jnj.com (K.F.Y.C.); lparkwyl@ITS.JNJ.com (L.P.-W.)
* Correspondence: wallis.cjd@gmail.com; Tel.: +1-(615)-322-2101

**Simple Summary:** Despite significant advancements in the treatment of metastatic prostate cancer, a validated prognostic tool for patients with de novo metastatic castration-sensitive prostate cancer (mCSPC) is still lacking. Using population-based data from Ontario, Canada, we examined the prognostic association between common laboratory tests and survival for patients with mCSPC. These low-cost commonly available laboratory tests, including neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, albumin, hemoglobin, PSA decrease and PSA nadir, were significantly associated with OS. They can provide important prognostic information and should be utilized more frequently among patients with newly diagnosed mCSPC.

**Abstract:** De novo cases of metastatic prostate cancer (mCSPC) are associated with poorer prognosis. To assist in clinical decision-making, we aimed to determine the prognostic utility of commonly available laboratory-based markers with overall survival (OS). In a retrospective population-based study, a cohort of 3556 men aged ≥66 years diagnosed with de novo mCSPC between 2014 and 2019 was identified in Ontario (Canada) administrative database. OS was assessed by using the Kaplan–Meier method. Multivariate Cox regression analysis was performed to evaluate the association between laboratory markers and OS adjusting for patient and disease characteristics. Laboratory markers that were assessed include neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), albumin, hemoglobin, serum testosterone and PSA kinetics. Among the 3556 older men with de novo mCSPC, their median age was 77 years (IQR: 71–83). The median survival was
18 months (IQR: 10–31). In multivariate analysis, a statistically significant association with OS was observed with all the markers (NLR, PLR, albumin, hemoglobin, PSA decrease, reaching PSA nadir and a 50% PSA decline), except for testosterone levels. Our findings support the use of markers of systemic inflammation (NLR, PLR and albumin), hemoglobin and PSA metrics as prognostic indicators for OS in de novo mCSPC.

**Keywords:** mCSPC; prognosticators; lab tests; OS; population-based

1. Introduction

Prostate cancer (PCa) is the most common solid organ tumor in Canadian men [1–3]. Nearly a quarter of all PCa patients will have metastatic disease at some point in their disease trajectory, with a third of having metastatic disease at diagnosis (de novo) [1,4] which are associated with worse prognosis [5,6]. In the hormone-naïve setting, the median overall survival (OS) among patients with metastatic prostate cancer receiving conventional treatment (i.e., androgen-deprivation therapy (ADT)) is 36–40 months [4,5,7] and is reportedly much worse (<20 months) in the elderly population [8]. Recently, numerous studies have demonstrated benefits of ADT intensification regimens in mCSPC patients. The addition of chemotherapy (docetaxel) [7,9,10] or androgen receptor-axis-targeted therapies (abiraterone acetate + prednisone [11–13], apalutamide [14] and enzalutamide [15]) to ADT have been found to result in improved overall survival (OS) and progression-free survival (PFS).

As the treatment for mCSPC becomes more complex with emerging systemic and local therapy, common indicators of disease burden can assist in clinical decision-making and improve patient management. At present, management is tailored based on metastatic burden, as described in CHAARTED, and risk stratification, as based on LATITUDE criteria. A number of prognostic models have been developed for patients with metastatic PCa [16–20]. These include the Glass model (2003) [18], Gravis model (2015) [19] and, most recently, Akamatsu [20] model. However, these models have their own limitations. For example, the Glass model was built from a trial that was conducted in an era when use of PSA was uncommon. The Gravis model was based on a very small number of patients with relatively low discriminatory ability and the Akamatsu model was based on a retrospective review of a small number of patients with only Asian ethnicity. Consequently, these models should be validated in larger, more diverse, real-world populations [21]. Additionally, the prognostic values of other easily accessible laboratory parameters (e.g., markers of inflammation, testosterone levels, etc.) were unexplored in these models in de novo mCSPC, despite evidence supporting their prognostic ability in the metastatic castrate resistant prostate cancer (mCRPC) population [22–24].

We, therefore, performed a large population-based study on elderly patients aged 66 years and above with de novo mCSPC from a Canadian province to determine the prognostic association of several commonly available laboratory-based markers with overall survival (OS).

2. Materials and Methods

2.1. Study Design

A retrospective population-based cohort study was conducted by using province-wide linked administrative data.

2.2. Setting

Canada has a universal, publicly funded healthcare system where about 70% of total health expenditure comes from general taxation of the federal and 13 provincial/territorial governments [25,26]. Ontario is the most populous province in Canada, with almost 14.7 million residents, representing about 40% of the Canadian population [27]. In On-
tario, cancer-care services are coordinated by Cancer Care Ontario, a government agency responsible for collecting cancer data, developing clinical standards, and planning and implementing cancer services through 14 regional cancer centers [28].

2.3. Data Sources
The patient-level dataset was created by using health administrative databases housed at IC/ES (www.ices.on.ca, accessed on 31 March 2020), an independent, non-profit research corporation funded by the Ministry of Health and Long-Term Care. The databases contain publicly funded administrative health service records for the Ontario population eligible for health coverage. They were linked by using encrypted patient-specific identifiers. Table A1 presents a description of databases used to create the study dataset.

2.4. Study Population
A cohort of de novo mCSPC patients in the province was defined among men aged ≥66 years who had metastatic PCa at the time of diagnosis (i.e., index date) between 1 January 2014 and 31 March 2020. Subjects were excluded if they were age ≤65, had a missing or invalid identification number, were not eligible for provincial health insurance coverage in the 2 years prior to diagnosis or had missing data for key exposure variables for analyses. Because the Ontario Drug Benefit (ODB) coverage starts at 65 years of age, we included patients aged ≥66 years to capture at least one year of full prescription data prior to the index date. This allowed for identification of an inception cohort and complete treatment ascertainment.

2.5. Outcome and Covariates
The primary end point used in the study was OS, defined as the time from PCa diagnosis to date of death from any cause. Patients without events were censored at their last date of follow-up. We evaluated the association of several exposure variables of interest with OS: markers of systemic inflammation (baseline neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR) and albumin), baseline hemoglobin, baseline testosterone levels and prostate-specific antigen (PSA) metrics (50% PSA decrease, PSA percentage change from baseline, PSA nadir <0.1 ng/mL). These exposure variables were selected because they are readily available from laboratory tests and have been implicated in the prognosis of prostate cancer [22–24,29,30]. Of note, all laboratory tests were performed in the 3 months preceding the index date. If the test was not available prior to the index date, then we used a test value available within 2 months following the index date but no more than 5 days after ADT initiation. In either case, the test value that was closest to the index date was selected. In a sensitivity analysis, we considered laboratory tests performed in the 6 months preceding the index date. As an exploratory analysis, we evaluated the association of these laboratory markers with time to emergence of castrate resistance.

The study population was described at baseline, using a set of variables that included sociodemographic characteristics (age, socioeconomic status, Local Health Integration Network (LHIN), rurality, PCa attributes such as PSA at diagnosis, Gleason score and health status (Charlson Comorbidity Index, history of key comorbid conditions other than PCa, including diabetes, myocardial infarction, congestive heart failure, and liver or kidney disease), as well as healthcare use (number of general practitioner (GP) visits, status of being a long-term care (LTC) resident and history of hospitalizations). Details on each variable are briefly presented in Table A2.

2.6. Statistical Analysis
Descriptive statistics (counts (%); mean and standard deviation (SD) or median with inter-quartile range (IQR)) were reported for the baseline patient characteristics. Median was used to describe years, as well as PSA, at diagnosis (due to its non-normal nature). Overall survival (OS) (median with IQR) for the entire cohort was calculated by using the Kaplan–Meier method.
Utilizing a complete case analysis, we fitted a Cox proportional hazard model to assess the association between each of the exposure variables and OS. Hazard ratios (HRs) and their associated 95% confidence intervals (CI) were computed. We first examined the relationship between each exposure lab test and overall survival by using restricted cubic splines (RCS) with 5 knots to assess for non-linearity. We identified significant non-linearity, and, to provide clinically interpretable estimates, the exposure variables were categorized into quintiles, with the lowest quintile (Q1) used as the reference. We also tested a binary categorization of the non-ratio type of exposure variables, i.e., “normal vs. below normal” for albumin, hemoglobin, testosterone and “yes vs. no” for 50% PSA decrease and PSA nadir <0.1 ng/mL. The models were compared by using negative log-likelihood (NLL) values. Results for all the models were reported. The assumption of proportionality was tested by the examination of Schoenfeld residuals.

Each Cox model was adjusted for baseline characteristics. All the characteristics were introduced to the models as dichotomized or categorical independent variables, with the exception of GP visits (continuous) and PSA (splines). For the latter, the baseline PSA values were transformed by using restricted cubic splines (RCS) with 5 knots to account for non-linearity. Table A3 provides more detail on categorization of the independent covariates, including the exposure variables. There was no evidence of multicollinearity between the covariates in the model. All analyses were conducted in SAS. The study received research ethics approval from Advarra IRB (Pro00037601).

3. Results
3.1. Patient Characteristics

From 2014 to 2019, we identified 3556 patients of age 66 years or older who presented with de novo metastatic PCa. The baseline characteristics are summarized in Table 1. The median age of the patients was 77 years (IQR: 71–83). Table 2 provides a distribution of patients’ laboratory tests (i.e., exposure variables) across the quintiles. The total number of patients with corresponding lab results available for modeling ranged from 290 (testosterone) to 2775 (PSA).

3.2. Association between Laboratory Tests and Overall Survival

The median survival of the entire population of de novo mCSPC patients was 18 months (IQR: 10–31). The adjusted Cox regression analyses showed that all exposure variables, except serum testosterone, were significantly associated with OS (Tables 3 and 4).

3.2.1. Neutrophil to Lymphocyte (NLR) and Platelet to Lymphocyte Ratios (PLR)

After adjusting for the baseline characteristics, men with higher NLR (quintile 5) had significantly greater relative risk of mortality than those with lower NLR (quintile 1) (hazard ratio (HR) Q5 vs. Q1: 1.55; 95% confidence intervals (CI): 1.27–1.90). Similarly, patients with high PLR (quintile 5) had increased risk of mortality compared to those with low PLR (quintile 1) (HRQ5 vs. Q1: 1.36; 95% CI: 1.11–1.65).

3.2.2. Albumin

After adjusting for confounders, patients with high albumin levels (quintile 5), had significantly decreased risk of mortality (HRQ5 vs. Q1: 0.48; 95% CI: 0.36–0.63) compared to men with low albumin (quintile 1).

3.2.3. Hemoglobin

Similarly, hemoglobin levels were associated with OS. Men with high hemoglobin levels (quintile 5) had a significantly decreased risk of mortality compared to patients with low hemoglobin (quintile 1) (HRQ5 vs. Q1: 0.42; 95% CI: 0.33–0.52).
Table 1. Baseline characteristics.

| Parameter                              | Value         |
|----------------------------------------|---------------|
| **Patient demographics**               |               |
| **Age categories**                     |               |
| Median (IQR), years                    | 77 (71-83)    |
| Age 66–75, n (%)                       | 1576 (44.3%)  |
| Age 76–85, n (%)                       | 1382 (38.9%)  |
| Age > 85, n (%)                        | 598 (16.8%)   |
| **Rurality**                           |               |
| Non-rural, n (%)                       | 3156 (88.8%)  |
| **Medical care and comorbidity**       |               |
| Comorbidity (Charlson Index), Mean ± SD| 0.33 ± 0.99   |
| Number of GP visits, Mean ± SD         | 9.23 ± 8.49   |
| Hospitalization, n (%)                 | 593 (16.7%)   |
| Ever LTC resident, n (%)               | 50 (1.4%)     |
| Diabetes, n (%)                        | 261 (7.3%)    |
| History of MI, n (%)                   | 87 (2.4%)     |
| History of CVA, n (%)                  | 67 (1.9%)     |
| History of CHF, n (%)                  | 252 (7.1%)    |
| History of COPD, n (%)                 | 211 (5.9%)    |
| History of HTN, n (%)                  | 362 (10.2%)   |
| History of arrhythmia, n (%)           | 52 (1.5%)     |
| History of dementia, n (%)             | 319 (9.0%)    |
| History of liver disease, n (%)        | 37 (1.0%)     |
| History of renal disease, n (%)        | 311 (8.7%)    |
| **Prostate cancer characteristics**    |               |
| PSA at diagnosis (3 months)            | -             |
| PSA test, n (%)                        | 2775 (78.0%)  |
| Median (IQR)                           | 85 (24–346)   |
| **Biopsy Gleason Score**               |               |
| <7, n (%)                              | 13 (0.4%)     |
| 7, n (%)                               | 301 (8.5%)    |
| >7, n (%)                              | 1426 (40.1%)  |
| Unknown, n (%)                         | 1816 (51.1%)  |
| **Systemic therapies received**        |               |
| Conventional ADT, n (%)                | 2794 (78.6%)  |
| ADT plus Docetaxel, n (%)              | 399 (11.2%)   |
| ADT plus AA + P, n (%)                 | 52 (1.5%)     |
| Non-ADT, n (%)                         | 311 (8.7%)    |

PSA, prostate-specific antigen; HTN, hypertension; IQR, inter-quartile range; SD, standard deviation; COPD, chronic obstructive pulmonary disorder; CHF, congestive heart failure; CVA, cerebrovascular accidents; MI, myocardial infarction; LTC, long-term care; ADT, androgen deprivation therapy; AA + P, abiraterone acetate plus prednisone.

3.2.4. PSA, % Drop from Baseline

Compared with patients with the steeper decline in PSA from the baseline within 3 months (quintile 5), patients with a flatter PSA decline (quintile 1) had a significantly greater risk of dying (HR$_{Q5}$ vs. Q1: 0.21; 95% CI: 0.18–0.26). Patients who were able to reach the prespecified lowest PSA (<0.1 ng/mL) and patients who had at least a 50% decline in PSA at 3 months had a significantly decreased risk of overall mortality: HR$_{PSA\text{ nadir}}$: 0.27 (95% CI: 0.22–0.32) and HR$_{50\%\text{PSA}}$: 0.26 (95% CI: 0.22–0.31), respectively.

3.2.5. Testosterone

There was no observed association between baseline testosterone levels and OS (HR$_{Q5}$ vs. Q1: 0.99; 95% CI: 0.54–1.82).

Compared to the model based on binary categorization of the variables (based on lower limit of normal), the quintile-based stratification showed superior results for albumin (negative log-likelihood (NLL): 7640.6 vs. 7624.8, $p = 0.012$) and hemoglobin (NLL: 14310.0 vs. 14291.8, $p < 0.001$) but no difference was seen for testosterone ($p = 0.327$).
(Table A4). For exploratory analysis, no significant associations were observed between the exposure variables and the time to castrate resistance.

**Table 2.** Quintile values of laboratory tests (exposure variables).

| Laboratory Test | Parameter | Quintile 1 | Quintile 2 | Quintile 3 | Quintile 4 | Quintile 5 | Total |
|-----------------|-----------|------------|------------|------------|------------|------------|-------|
| Neutrophil to lymphocyte ratio | No. of patients | n = 410 | n = 411 | n = 407 | n = 411 | n = 410 | n = 2049 |
| Mean ± SD | 1.4 ± 0.4 | 2.3 ± 0.2 | 3.1 ± 0.2 | 4.2 ± 0.5 | 8.9 ± 6.1 | 4.0 ± 3.8 |
| Platelet to lymphocyte ratio | No. of patients | n = 406 | n = 406 | n = 406 | n = 407 | n = 406 | n = 2031 |
| Mean ± SD | 69.2 ± 22.2 | 112.1 ± 9.5 | 145.1 ± 10.0 | 190.2 ± 17.5 | 324.3 ± 123.4 | 168.2 ± 104.4 |
| Albumin (g/L) | No. of patients | n = 222 | n = 205 | n = 221 | n = 178 | n = 241 | n = 1067 |
| Mean ± SD | 28.9 ± 3.7 | 35.5 ± 1.1 | 39.0 ± 0.8 | 41.5 ± 0.5 | 44.7 ± 1.7 | 37.9 ± 5.9 |
| Hemoglobin (g/L) | No. of patients | n = 404 | n = 414 | n = 404 | n = 425 | n = 418 | n = 2065 |
| Mean ± SD | 95.6 ± 11.7 | 117.9 ± 4.4 | 130.4 ± 2.8 | 140.6 ± 2.8 | 154.6 ± 7.6 | 128.1 ± 21.2 |
| Testosterone (nmol/L) | No. of patients | n = 59 | n = 56 | n = 59 | n = 58 | n = 58 | n = 290 |
| Mean ± SD | 0.3 ± 0.2 | 3.4 ± 2.0 | 8.7 ± 1.0 | 12.8 ± 1.4 | 21.4 ± 6.1 | 9.3 ± 8.0 |
| PSA (nmol/L) | No. of patients | n = 555 | n = 555 | n = 556 | n = 554 | n = 555 | n = 2775 |
| Mean ± SD | 9.7 ± 4.7 | 32.1 ± 9.8 | 89.2 ± 25.5 | 270.8 ± 95.2 | 1748.1 ± 2116.3 | 429.9 ± 1157.3 |

**Table 3.** Cox proportional hazards model of time to death by laboratory tests stratified by quintiles (Q).

| Characteristics | Adjusted HR (95% CI) | p-Value |
|-----------------|----------------------|---------|
| | Q2 vs. Q1 * | Q3 vs. Q1 * | Q4 vs. Q1 * | Q5 vs. Q1 * |
| NLR | 1.08 (0.88–1.31) | 1.08 (0.88–1.31) | 1.44 (1.18–1.75) | 1.55 (1.27–1.90) |
| PLR | 0.95 (0.77–1.16) | 1.08 (0.88–1.32) | 1.23 (1.01–1.50) | 1.36 (1.11–1.65) |
| Albumin | 0.77 (0.60–0.99) | 0.65 (0.51–0.84) | 0.55 (0.42–0.73) | 0.48 (0.36–0.63) |
| Hemoglobin | 0.71 (0.59–0.85) | 0.56 (0.47–0.69) | 0.42 (0.34–0.52) | 0.42 (0.33–0.52) |
| Testosterone | 1.56 (0.89–2.74) | 0.78 (0.43–1.42) | 1.12 (0.61–2.08) | 0.99 (0.54–1.82) |
| PSA% drop from baseline within 3 months | 0.50 (0.43–0.59) | 0.38 (0.32–0.46) | 0.26 (0.21–0.32) | 0.21 (0.18–0.26) |

* Q1 is the reference quintile; Q5 represents the highest value. The models were adjusted for baseline variables: age, socioeconomic status, LHIN, rurality, PSA at diagnosis, Gleason score, Charlson Comorbidity Index, history of diabetes, myocardial infarction, congestive heart failure, cardio-vascular accidents, liver or kidney disease, hypertension, chronic obstructive pulmonary disease, arrhythmia and dementia; number of GP visits, status of a LTC resident and history of hospitalizations.

**Table 4.** Cox proportional hazards model of time to death by laboratory markers stratified into binary variables by lower limit of normal level (binary categorization).

| Characteristics | Value | Adjusted HR (95% CI) | p-Value |
|-----------------|-------|----------------------|---------|
| Albumin | Normal (34–54 g/L) vs. Below (<34 g/L) | 0.60 (0.49–0.74) | <0.001 |
| Hemoglobin | Normal (130–175 g/L) vs. Below (<130 g/L) | 0.55 (0.48–0.63) | <0.001 |
| Testosterone | Normal (9.5–30 nmol/L) vs. Below (<9.5 nmol/L) | 0.78 (0.52–1.17) | 0.2288 |
| Achieve PSA nadir (<0.1 ng/mL) | Yes vs. No | 0.27 (0.22–0.32) | <0.001 |
| 50% PSA decline at 3 months | Yes vs. No | 0.26 (0.22–0.31) | <0.001 |

The models were adjusted for baseline variables: age, socioeconomic status, LHIN, rurality, PSA at diagnosis, Gleason score, Charlson Comorbidity Index, history of diabetes, myocardial infarction, congestive heart failure, cardio-vascular accidents, liver or kidney disease, hypertension, chronic obstructive pulmonary disease, arrhythmia and dementia; number of GP visits, status of a LTC resident and history of hospitalizations.
4. Discussion

In this study, we examined the prognostic value of several commonly used laboratory markers in a large cohort of patients aged 66 years and older with de novo mCSPC. The results indicate that patients with higher NLR or PLR had a 55% and 36% relative increase in the risk of mortality compared to those with low NLR or PLR, respectively. In contrast, patients with higher levels of albumin and patients with higher levels of hemoglobin had a 52% and 58% reduced risk of death respectively, compared to those with lower values. Patients with a faster rate of decline in PSA levels and those who ultimately achieved the PSA nadir were found to have superior OS compared to those with a slower decline in PSA levels and those who failed to achieve the predefined PSA nadir. We did not find any association of testosterone levels with OS; however, this comparison was limited by a relatively smaller sample size and inter-assay variability. Moreover, the observed lack of association between the markers and time to castration resistance suggests that other PCa disease-specific characteristics may need to be explored for prognostic use of disease progression among this population.

Emerging evidence has demonstrated the pivotal role of chronic inflammation on tumorigenesis and disease progression. Lymphocytopenia and higher platelet counts trigger cancer progression and hematogenous dissemination. NLR and PLR, as biomarkers for systemic inflammatory response, have been found to be associated with poor prognosis in mCRPC and mCSPC [31–33]. Our findings concur with these results. Further, our finding of poor overall survival in patients with hypoalbuminemia could be attributed to a number of factors. Hypoalbuminemia is essentially caused by chronic systemic inflammatory activity including ageing itself. Hypoalbuminemia results in diminished muscle mass; it bears detrimental impact on cognitive and immune function and, consequently, leads to diminished life expectancy [34]. In contrast to our findings, Akamatsu et al. did not find any association of albumin levels with OS. The differences in study populations including age, different jurisdictions and different healthcare systems could be some of the plausible explanations behind these conflicting observations.

Anemia in men with advanced prostate cancer may be caused by several factors, including androgen deprivation, decline in nutritional status, bone marrow infiltration, treatment-related toxicity and the chronic inflammatory state. Low levels of hemoglobin have been reported to portend worse overall and cancer-specific survival in patients with mCSPC [35,36] independent of the metastatic burden. Our findings are in agreement with these results. This association could be explained by anemia-induced dimerization of hypoxia-inducible factor 1 alfa (HIF-1α). HIF-1α triggers expression of various oncogenes, conferring resistance to chemotherapy and radiotherapy and inducing cancer progression [37–39].

The association of PSA kinetics with OS is controversial. Although the Glass model showed PSA to be an important prognostic factor, Akamatsu et al. did not include PSA in their final model. Petrylak et al. showed that PSA-level declines of at least 20–40%, in addition to a PSA velocity at 3 months after beginning treatment with docetaxel, were associated with overall survival [40]. A recent post hoc analysis of LATITUDE study showed significant correlation of time-to-PSA progression with radiographic progression-free survival and OS [41]. Patients reaching PSA ≤0.1 ng/mL within 6 months had a significantly longer radiographic progression-free survival or OS. Additionally, more than 50% response in PSA was associated with decreased risk of death (HR, 0.44; 95% CI 0.27–0.70). These findings are concordant with our results. Overall, these findings suggest that early PSA kinetics after treatment could reflect a long-term overall outcome in this patient population.

Our study is subject to a number of limitations. First, the retrospective nature from which these prognostic associations were derived should be validated with results from prospective de novo mCSPC studies. Second, the lack of radiographic data to differentiate between patients with high vs. low volume of metastatic burden and the lack of information on these laboratory variables in a substantial proportion of patients were limiting factors.
The overall frequency of PSA measurements in an individual patient was low, leading to missed opportunity to acquire valuable information. The frequency and timing of PSA determination also varied among treating oncologists. Our findings should be considered in light of these confounders. Third, our study cohort was relatively older compared to those included in the randomized controlled trials. Moreover, this analysis is based on patients with heterogeneous clinical backgrounds not controlled for in the context of a prospective clinical trial. Finally, factors such as patient or clinician preference, baseline psychological distress, anxiety and health-related quality of life, which might affect treatment choice and overall survival, were not captured in our study [42].

5. Conclusions

Our study confirmed the potential utility of markers of systemic inflammation such as NLR, PLR and albumin to serve as prognostic indicators for overall survival in a large cohort of de novo mCSPC. Our findings also supported the use of PSA metrics as prognostic indicators for survival in the de novo mCSPC. Overall, these findings suggest that these biomarkers should be considered among other clinical features to tailor treatment decision in men with de novo metastatic castrate sensitive prostate cancer.

Author Contributions: Conceptualization and design, C.J.D.W., B.S., S.C.M., R.J.H., I.C., N.S.B., C.F., G.T.G., R.F., S.R., K.L.N., T.N., S.J.H., F.S., H.H., K.F.Y.C., L.P.K., and S.M.; acquisition, analysis or interpretation of data, C.J.D.W., K.F.C., L.P.K., B.S. and S.M.; drafting of the manuscript, C.J.D.W., K.F.Y.C., L.P.K., B.S. and S.M.; critical revision of the manuscript for important intellectual content, C.J.D.W., B.S., S.C.M., R.J.H., I.C., N.S.B., C.F., G.T.G., R.F., S.R., K.L.N., T.N., S.J.H., F.S., H.H., K.F.Y.C., L.P.K., and S.M; statistical analysis, C.J.D.W. and L.P-K.; project administration C.J.D.W., K.F.Y.C. and L.P.K.; supervision, C.J.D.W. and S.M. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by Janssen Inc. grant numbers NOPRODPCR0001.

Institutional Review Board Statement: Research ethics approval from Advarra IRB (Pro00037601).

Informed Consent Statement: Patient consent was waived because ICES is a named prescribed entity, under section 45(1) of the Personal Health Information Protection Act, 2004, it has statutory authority to conduct health services research without consent using anonymized administrative data.

Data Availability Statement: Health administrative databases for Ontario, Canada, are housed at IC/ES (www.ices.on.ca, accessed on 31 March 2020).

Acknowledgments: IQVIA team was hired by Janssen Inc. to assist with writing and editing the manuscript. The initial ideas, study concepts, analyzed data, its interpretation and the clinical significance were provided to them by Janssen Inc.

Conflicts of Interest: C.J.D.W., consulting or advisory role (Janssen Oncology); B.S., honoraria, consulting role and speakers’ bureau (Abbvie, Astellas Pharma, Bayer, Janssen, Knight Pharmaceuticals, TerSera), research funding (Astellas Pharma, Janssen, Merck); S.C.M., consulting or advisory role (Astellas Pharma, Bayer, Janssen, TerSera); R.J.H., honoraria (Abbvie, Amgen, Astellas Pharma, Bayer, Janssen), consulting role (Janssen), research funding (Bayer, Janssen); I.C., honoraria (Abbvie, Ferring), consulting or advisory role (Janssen); N.S.B., honoraria (Astellas Pharma, Eisai, Ipsen, Janssen, Merck, Pfizer), consulting or Advisory role (Astellas Pharma, AstraZeneca, Bayer, Bristol-Myers Squibb, Eisai, Ipsen, Janssen, Merck, Pfizer, Roche); C.F., honoraria (Astellas Pharma, AstraZeneca, Bayer, Lilly, Merck, Novartis, Pfizer), consulting or advisory role (AstraZeneca, Odonate Therapeutics, Janssen, Pfizer, Roche), speakers’ bureau (Janssen), research funding (Astellas Pharma, AstraZeneca, Immunomedics, Janssen, Merck, Novartis, Pfizer, Roche, Sanofi, Seattle Genetics); G.T.G., honoraria (Amgen, Astellas Pharma, Bayer, Janssen, Merck), consulting or advisory role (Amgen, Astellas Pharma, Bayer, Janssen, Merck), expert testimony (Janssen); R.F., honoraria (Bayer, Merck, Pfizer), consulting or advisory role (Bayer, Janssen, Novartis, Pfizer); S.R., research funding (Abbvie); K.L.N., consulting or advisory role (AstraZeneca, Bristol-Myers Squibb, Ipsen, Janssen Oncology, Merck, Pfizer, Roche Canada, Sanofi), speakers’ bureau (Merck); T.N., honoraria (Abbvie, Astellas Pharma, Bayer, Janssen Oncology, Sanofi, TerSera), consulting or advisory role (Abbvie, Bayer, Janssen Oncology, Sanofi, TerSera), research funding (Astellas Pharma, Bayer, Sanofi, TerSera);
Appendix A

Table A1. Description of databases that informed the development of the study dataset.

| Database Name | Description |
|---------------|-------------|
| **Ontario Cancer Registry (OCR)** | The OCR is collected by Cancer Care Ontario and contains information on all Ontario residents who have been newly diagnosed with cancer (“incidence”) or who have died of cancer (“mortality”). All new cases of cancer are registered, except non-melanoma skin cancer. |
| **Registered Person Database (RPDB)** | The RPDB provides basic demographic information (age, sex, location of residence, date of birth and date of death for deceased individuals) for those issued an Ontario health insurance number. The RPDB also indicates the time periods for which an individual was eligible to receive publicly funded health insurance benefits and the best known postal code for each registrant on July 1st of each year. |
| **Continuing Care Reporting System (for Chronic Care) (CCRS)** | The CCRS database is compiled by the Canadian Institute for Health Information and contains demographic, clinical, functional, and resource utilization information for individuals receiving facility-based continuing care (also known as extended, auxiliary, or complex chronic care) in Ontario hospitals and residential care providing 24 h nursing services (i.e., nursing home). Clinical assessment data (on the physical, functional, cognitive and social domains of health) are ascertained by using the Resident Assessment Instrument-Minimum Data Set (RAI-MDS) version 2.0, which is administered by trained healthcare professionals. |
| **Ontario Congestive Heart Failure dataset (CHF)** | The Ontario Congestive Heart Failure Database is an ICES-derived cohort that was created by using a definition of ≥2 physician billing claims with a diagnosis of CHF (OHIP diagnosis code 428) and/or ≥1 inpatient hospitalization or same-day surgery record with a diagnosis of CHF (ICD-9 diagnosis code 428; ICD-10 diagnosis code I50; in the primary diagnostic code space) in a two-year period applied to hospitalization (DAD), same-day surgery (SDS), and physician billing claims (OHIP) data to determine the diagnosis date for incident cases of CHF in Ontario. |
| **Ontario Chronic Obstructive Pulmonary Disease Dataset (COPD)** | The Ontario COPD Database is an ICES-derived cohort that is created by using two separate algorithms applied to inpatient hospitalization (DAD), same-day surgery (SDS) records, and physician billing claims (OHIP) data to determine the diagnosis date for incident cases of COPD in Ontario. In an algorithm which maximizes sensitivity, the definition for COPD is any physician billing claim with a diagnosis for COPD (OHIP diagnosis codes 491, 492 and 496) or any inpatient hospitalization or same-day surgery record with a diagnosis for COPD (ICD-9 diagnosis codes 491, 492, and 496; ICD-10 diagnosis codes J41-J44; in any diagnostic code space). |
| **Discharge Abstract Database (DAD)** | The DAD is compiled by the Canadian Institute for Health Information and contains administrative, clinical (diagnoses and procedures/interventions), demographic, and administrative information for all admissions to acute care hospitals, rehab, chronic, and day surgery institutions in Ontario. At ICES, consecutive DAD records are linked together to form “episodes of care” among the hospitals to which patients have been transferred after their initial admission. |
Table A1. Cont.

**Ontario Hypertension Dataset (HYPER)**

The Ontario Hypertension Database is an ICES-derived cohort and created by using a definition of ≥2 physician billing claims with a diagnosis of hypertension (OHIP diagnosis codes: 401–405) and/or ≥1 inpatient hospitalization or same-day surgery record with a diagnosis of hypertension (ICD-9 diagnosis codes: 401–405; ICD-10 diagnosis codes: I10-I13, I15; in any diagnostic code space) in a two-year period applied to hospitalization (DAD), same-day surgery (SDS), and physician billing claims (OHIP) data to determine the diagnosis date for incident cases of hypertension in Ontario. Physician claims and hospitalizations with a diagnosis of hypertension occurring within 120 prior to and 180 days after a gestational hospitalization record are excluded.

**National Ambulatory Care Reporting System (NACRS)**

The NACRS is compiled by the Canadian Institute for Health Information and contains administrative, clinical (diagnoses and procedures), demographic, and administrative information for all patient visits made to hospital- and community-based ambulatory care centers (emergency departments, day surgery units, hemodialysis units, and cancer care clinics). At ICES, NACRS records are linked with other data sources (DAD and OMHRS) to identify transitions to other care settings, such as inpatient acute care or psychiatric care.

**Ontario Diabetes Dataset (ODD)**

The Ontario Diabetes Database is an ICES-derived cohort and is created by using algorithms applied to inpatient hospitalization (DAD) records, same-day surgery (SDS) records and physician billing claims (OHIP) data to determine the diagnosis date for incident cases of diabetes in Ontario. For adults aged 19 years and greater, the definition for diabetes is two physician billing claims with a diagnosis for diabetes (OHIP diagnosis code 250) or one inpatient hospitalization or same-day surgery record with a diagnosis for diabetes (ICD-9 diagnosis code 250; ICD-10 diagnosis codes E10, E11, E13 and E14; in any diagnostic code space) within a 2-year period. Physician claims and hospitalizations with a diagnosis of diabetes occurring within 120 prior to and 180 days after a gestational hospitalization record were excluded.

**Ontario Health Insurance Plan Claims Database (OHIP)**

OHIP claims data received by ICES contain most claims paid for by the Ontario Health Insurance Plan. The data cover all healthcare providers who can claim under OHIP (this includes physicians, groups, laboratories and out-of-province providers). Approximately 95% of specialists and 50% of primary care physicians receive the majority of their income from fee-for-service (FFS). However, all physicians, with the exception of the few hundred family physicians who work in Community Health Centres, are required to submit shadow billings for their non-FFS services. A shadow-billing claim is identical to an FFS claim except that the payment amount is $0.00. Shadow-billings have an explain code of “I2”. Physicians are often provided with cash incentives to encourage them to submit shadow-bill. Requiring physicians to shadow-bill helps to ensure that the OHIP data accurately (more-or-less) reflect the utilization of physician services in Ontario.

**Ontario Myocardial Infarction Dataset (OMID)**

The Ontario Myocardial Infarction Database is an ICES-derived cohort and contains records of all inpatient hospital admissions for acute MIs (ICD-9 diagnosis code 410; ICD-10 diagnosis code I21; in the primary diagnostic code space) in Ontario since 1991. These admissions are ascertained by using the DAD and exclude in-hospital events and admissions where there had been a previous discharge for acute myocardial infarction in the previous year. This cohort of patients with acute MI hospital admissions is linked with hospitalization (DAD), same-day surgery (SDS) and physician-billing-claims data (OHIP) to create indicators of hospital readmission after discharge and receipt of cardiac procedures during and after the initial hospital admission.
Ontario Laboratories Information System (OLIS)

Starting in 2012 all Public Health Ontario laboratories joined OLIS. As of August 2016, OLIS has completed connections with additional hospital laboratories in 13 out of 14 LHINs. As of February 2017, Hamilton Health Sciences is now fully contributing lab results into OLIS. The OLIS library at ICES consists of three distinct datasets: (1) lab orders contain the order-level information, including patient demographics and provider information; (2) test requests contain the test ID code (called Test Request Code) and specimen information, in addition to ordering, performing and reporting facilities among other variables; and (3) observations contain the test result information, including the result ID code (called Observation Code), values and units.

New Drug Funding Program (NDFP)

The New Drug Funding Program (NDFP) is one of four publicly funded drug programs under the Ontario Public Drug Programs (OPDP). Administered by Cancer Care Ontario, the NDFP funds new, and often very expensive, cancer drugs. The program was created in 1995 to ensure that Ontario patients have equal access to high-quality intravenous (IV) cancer drugs.

Cancer Activity Level Reporting (ALR)

Activity Level Reporting (ALR) data represent the basic set of data elements required to produce the quality, cost and performance indicators for the cancer system. The data elements constitute patient-level activity within the cancer system focused on radiation and systemic therapy services and outpatient oncology clinic visits. These data are also a key component of the Ontario Cancer Registry (OCR), which registers every malignant neoplasm diagnosed in Ontario.

Table A2. Definition of variables to describe baseline characteristics.

| Category                        | Description                                                                                                                                 |
|---------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------|
| Demographics                    | - Age at index date (from RPDB)                                                                                                           |
|                                 | - Socioeconomic status at index date (neighborhood income quintile)                                                                        |
|                                 | - Geographic region at index date (LHIN, rural vs. non-rural)                                                                               |
| Prostate cancer characteristics | - PSA (median, IQR) immediately prior to prostate cancer diagnosis (must be within 6 months prior to diagnosis; if none available prior to diagnosis, check for one within 2 months following diagnosis; if none available by these criteria, mark as missing), using LOINC codes LOINC 19197-3, 2857-1, 35741-8) |
|                                 | - Stage (OCR—best_stage_grp)                                                                                                              |
|                                 | - Grade (Gleason score)                                                                                                                    |
| General medical care            | - Comorbidity—Charlson (CCI; 2-year look-back, using DAD and SDS data, including index)                                                   |
|                                 | - Number of GP visits (spec = 00) in year prior to diagnosis                                                                               |
|                                 | - Hospitalization (inpatient for any reason) in year prior to diagnosis (yes/no)                                                          |
|                                 | - Ever resident of long-term care in year prior to diagnosis (yes/no)                                                                     |
Table A2. Cont.

| Category | Description |
|----------|-------------|
| -       | Diabetes diagnosis (ODD) (up to 2017) |
| -       | Myocardial infarction in 5 years prior to diagnosis (OMID) |

Since OMID only up to date until 2016, use OMID and DAD. Definition: either flagged in OMID and/or Main diagnosis hospitalization with ICD-10 I21 with no prior hospitalization for MI 1 year prior

- Cerebrovascular accident in 5 years prior to diagnosis (NACRS, DAD)
  ICD-10: I63.x, I67.81, I67.82
  DAD—Most responsible diagnosis
  NACRS—Main diagnosis

- Congestive heart failure (CHF ICES cohort) (up to 2017)
- COPD (COPD ICES cohort) (up to 2017)
- Hypertension (Hyper ICES cohort) (up to 2017)
- HED/hospitalization for arrhythmia in year prior to diagnosis (NACRS, DAD)
  ICD-10: I44.x, I45.x, I47.x, I48.x, I49.x
  DAD—Most responsible diagnosis
  NACRS—Main diagnosis

Specific comorbidity

- Diagnosis of dementia within 5 years of diagnosis (NACRS, DAD, OHIP)
  ICD-10: F01.x, F02.x, F03.x, G30.X, G31.83,
  DXCODE: 290
  DAD—Most responsible diagnosis
  NACRS—Main diagnosis
  OHIP—DXCODE

- Diagnosis of liver disease within 5 years prior to diagnosis (NACRS, DAD, OHIP)
  ICD-10: K70.x, K71.x, K72.x, K73.x, K74.x, K75.2, K75.3, K75.4, K75.8, K75.9, K76.9
  DXCODE: 571
  DAD—Most responsible diagnosis
  NACRS—Main diagnosis
  OHIP—DXCODE

- Diagnosis of renal disease within 5 years prior to diagnosis (NACRS, DAD, OHIP)
  ICD-10: N18.x, N19
  DXCODE: 585
  DAD—Most responsible diagnosis
  NACRS—Main diagnosis
  OHIP—DXCODE
Table A3. Categorization of the independent covariates.

| Quintile | No. of Patients | Min Value | Max Value |
|-----------|-----------------|-----------|-----------|
| Neutrophil to lymphocyte ratio value |
| 1         | 358             | 0         | 1.9       |
| 2         | 372             | 1.9       | 2.7       |
| 3         | 360             | 2.7       | 3.5       |
| 4         | 341             | 3.5       | 5.1       |
| 5         | 333             | 5.1       | 63.2      |
| Platelet to lymphocyte ratio value |
| 1         | 349             | 3.6       | 95.7      |
| 2         | 358             | 95.8      | 129.2     |
| 3         | 361             | 129.2     | 163.3     |
| 4         | 352             | 163.5     | 224       |
| 5         | 333             | 224.4     | 1062.5    |
| Albumin value |
| 1         | 185             | 17        | 33        |
| 2         | 177             | 33.2      | 37.5      |
| 3         | 189             | 38        | 40        |
| 4         | 166             | 40.1      | 42.7      |
| 5         | 220             | 43        | 53        |
| Hemoglobin value |
| 1         | 316             | 46        | 109       |
| 2         | 354             | 110       | 125       |
| 3         | 355             | 126       | 135       |
| 4         | 376             | 136       | 145       |
| 5         | 376             | 146       | 183       |
| Serum testosterone value |
| 1         | 59              | 0.1       | 0.6       |
| 2         | 55              | 0.7       | 6.6       |
| 3         | 57              | 6.8       | 10.3      |
| 4         | 58              | 10.4      | 15.2      |
| 5         | 57              | 15.3      | 46.8      |
| PSA response (% drop from baseline) in absolute value |
| 1         | 475             | 0         | 85.7      |
| 2         | 475             | 85.7      | 96.8      |
| 3         | 475             | 96.8      | 99.2      |
| 4         | 475             | 99.2      | 99.9      |
| 5         | 475             | 99.9      | 62547.1   |
Table A4. Comparison of negative log-likelihood values of quintile-based model vs. model based on binary categorization.

| Characteristics                              | Albumin | Hemoglobin | Testosterone |
|----------------------------------------------|---------|------------|--------------|
| Negative LLV for model using categorical classification (quintiles) | 7624.8  | 14,291.8   | 1466.1       |
| Negative LLV for model using bivariate classification | 7640.6  | 14,310.0   | 1469.6       |
| Difference of LLV in 2 models                | 15.8    | 18.21      | 3.45         |
| DF                                           | 3       | 2          | 3            |
| p-value                                      | 0.0012  | <0.001     | 0.327        |

The models were adjusted for baseline variables; LLV—log-likelihood value.

References
1. LeBlanc, A.G.; Demers, A.; Shaw, A. Recent trends in prostate cancer in Canada. Health Rep. 2019, 30, 12–17. [CrossRef]
2. Catton, C.; Joshua, A. Princess Margaret Cancer Centre Clinical Practice Guidelines: Prostate Cancer; 2015. Available online: https://www.uhn.ca/PrincessMargaret/Health_Professionals/Programs_Departments/Genitourinary_GU/Documents/CPG_GU_Prostate.pdf (accessed on 1 February 2021).
3. Canadian Cancer Statistics: A 2018 Special Report. Available online: www.cancer.ca.Canadian-Cancer-Statistics-2018-EN (accessed on 1 February 2021).
4. So, A.I.; Chi, K.N.; Danielson, B.; Fleshner, N.E.; Kapoor, A.; Niazi, T.; Pouliot, F.; Rendon, R.A.; Shayegean, B.; Sridhar, S.; et al. Canadian Urological Association-Canadian Urologic Oncology Group guideline on metastatic castration-naïve and castration-sensitive prostate cancer. Can. Urol. Assoc. J. J. L’Assoc. Des. Urol. Can. 2020, 14, 17–23. [CrossRef]
5. Mosillo, C.; Iacovelli, R.; Ciccarese, C.; Fantinel, E.; Bimbatti, D.; Brunelli, M.; Bisogno, I.; Kinspergher, S.; Buttigliero, C.; Tucci, M.; et al. De novo metastatic castration sensitive prostate cancer: State of art and future perspectives. Cancer Treat. Rev. 2018, 70, 67–74. [CrossRef]
6. Roy, S.; Morgan, S.C. Who Dies From Prostate Cancer? An Analysis of the Surveillance, Epidemiology and End Results Database. Clin. Oncol. (R. Coll. Radiol.) 2019, 31, 630–636. [CrossRef] [PubMed]
7. Sweeney, C.J.; Chen, Y.H.; Carducci, M.; Liu, G.; Jarrard, D.F.; Eisenberger, M.; Wong, Y.N.; Hahn, N.; Kohli, M.; Cooney, M.M.; et al. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. N. Engl. J. Med. 2015, 373, 737–746. [CrossRef]
8. Bernard, B.; Burnett, C.; Sweeney, C.J.; Rider, J.R.; Srdihar, S.S. Impact of age at diagnosis of de novo metastatic prostate cancer on survival. Cancer 2020, 126, 986–993. [CrossRef] [PubMed]
9. James, N.D.; Sydes, M.R.; Clarke, N.W.; Mason, M.D.; Dearneley, D.P.; Spears, M.R.; Ritchie, A.W.; Parker, C.C.; Russell, J.M.; Attard, G.; et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): Survival results from an adaptive, multarm, multistage, platform randomised controlled trial. Lancet 2016, 387, 1163–1177. [CrossRef]
10. Clarke, N.W.; Ali, A.; Ingleby, F.C.; Hoyle, A.; Amos, C.L.; Attard, G.; Brawley, C.D.; Calvert, J.; Chowdhury, S.; Cook, A.; et al. Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: Long-term survival results from the STAMPEDE trial. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 2019, 30, 1992–2003. [CrossRef] [PubMed]
11. Fizazi, K.; Tran, N.; Fein, L.; Matsubara, N.; Rodríguez-Antolín, A.; Alekseev, B.Y.; Ozguroglu, M.; Ye, D.; Feyerabend, S.; Protheroe, A.; et al. Abiraterone plus Prednisone in Metastatic Castration-Sensitive Prostate Cancer. N. Engl. J. Med. 2017, 377, 352–360. [CrossRef] [PubMed]
12. James, N.D.; De Bono, J.S.; Spears, M.R.; Clarke, N.W.; Mason, M.D.; Dearneley, D.P.; Ritchie, A.W.S.; Amos, C.L.; Gilson, C.; Jones, R.J.; et al. Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy. N. Engl. J. Med. 2017, 377, 338–351. [CrossRef] [PubMed]
13. Hoyle, A.P.; Ali, A.; James, N.D.; Cook, A.; Parker, C.C.; De Bono, J.S.; Attard, G.; Chowdhury, S.; Cross, W.R.; Dearneley, D.P.; et al. Abiraterone in "High"- and "Low-risk" Metastatic Hormone-sensitive Prostate Cancer. Eur. Urol. 2019, 76, 719–728. [CrossRef]
14. Chi, K.N.; Agarwal, N.; Bjartell, A.; Chung, B.H.; Pereira de Santana Gomes, A.J.; Given, R.; Juarez Soto, Á.; Merseburger, A.S.; Özgüröglu, M.; Uemura, H.; et al. Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer. N. Engl. J. Med. 2019, 381, 13–24. [CrossRef] [PubMed]
15. Davis, I.D.; Martin, A.J.; Stockler, M.R.; Begbie, S.; Chi, K.N.; Chowdhury, S.; Coskins, X.; Frydenberg, M.; Hague, W.E.; Horvath, L.G.; et al. Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer. N. Engl. J. Med. 2019, 381, 121–131. [CrossRef] [PubMed]
16. Halabi, S.; Lin, C.Y.; Kelly, W.K.; Fizazi, K.S.; Moul, J.W.; Kaplan, E.B.; Morris, M.J.; Small, E.J. Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer. J. Clin. Oncol. 2014, 32, 671–677. [CrossRef]

17. Armstrong, A.J.; Garrett-Mayer, E.S.; Yang, Y.C.; De Wit, R.; Tannock, I.F.; Eisenberger, M. A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: Data from TAX327 study analysis. Clin. Cancer Res. 2007, 13, 6396–6403. [CrossRef]

18. Glass, T.R.; Tangen, C.M.; Crawford, E.D.; Thompson, I. Metastatic carcinoma of the prostate: Identifying prognostic groups using recursive partitioning. J. Urol. 2003, 169, 164–169. [CrossRef]

19. Gravis, G.; Boher, J.M.; Fizazi, K.; Joly, F.; Priou, F.; Marino, P.; Latorzeff, I.; Delva, R.; Krakowski, I.; Laguerre, B.; et al. Prognostic Factors for Survival in Noncastrate Metastatic Prostate Cancer: Validation of the Glass Model and Development of a Novel Simplified Prognostic Model. Eur. Urol. 2015, 68, 196–204. [CrossRef]

20. Akamatsu, S.; Kubota, M.; Uozumi, R.; Narita, S.; Takahashi, M.; Mitsuzuka, K.; Hatakeyama, S.; Sakurai, T.; Kawamura, S.; Ishidoya, S.; et al. Development and Validation of a Novel Prognostic Model for Predicting Overall Survival in Treatment-naive Castration-Resistant Metastatic Prostate Cancer. Eur. Urol. Oncol. 2019, 2, 320–328. [CrossRef]

21. Coquet, J.; Bievre, N.; Billaut, V.; Seneviratne, M.; Magnani, C.J.; Bozkurt, S.; Brooks, J.D.; Hernandez-Boussard, T. Assessment of a Clinical Trial-Derived Survival Model in Patients With Metastatic Castration-Resistant Prostate Cancer. JAMA Netw. Open 2021, 4, e2031730. [CrossRef]

22. Miura, N.; Morii, K.; Mostafaei, H.; Quhal, F.; Sari Motlagh, R.; Abufaraj, M.; Pradere, B.; Aydh, A.; Laukhitina, E.; D’Andrea, D.; et al. Prognostic value of testosterone for the survival of prostate cancer patients: A systematic review and meta-analysis. Int. J. Clin. Oncol. 2020, 25, 1881–1891. [CrossRef]

23. Van Soest, R.J.; Templeton, A.J.; Vera-Badillo, F.E.; Mercier, F.; Sonpavde, G.; Amir, E.; Tombal, B.; Rosenthal, M.; Eisenberger, M.A.; Tannock, I.F.; et al. Neutrophil-to-lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: Data from two randomized phase III trials. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 2015, 26, 743–749. [CrossRef] [PubMed]

24. Tian, S.; Lei, Z.; Gong, Z.; Sun, Z.; Xu, D.; Piao, M. Clinical implication of prognostic and predictive biomarkers for castration-resistant prostate cancer: A systematic review. Cancer Cell Int. 2020, 20, 409. [CrossRef] [PubMed]

25. Martín, D.; Miller, A.P.; Quesnel-Vallières, A.; Caron, N.R.; Vissandjee, B.; Marchildon, G.P. Canada’s universal health-care system: Achieving its potential. Lancet 2018, 391, 1718–1735. [CrossRef]

26. Marchildon, G.P. Canada: Health system review. Health Syst. Transit. 2013, 15, 1–179. [PubMed]

27. Statistics Canada. Population by Year, by Province and Territory. Available online: https://www150.statcan.gc.ca/t1/tbl1/en/tv.action?pid=1710000501 (accessed on 1 February 2021).

28. Cancer Care Ontario: Regional Cancer Centres. Available online: https://www.cancercareontario.ca/en/find-cancer-services/regional-cancer-centres (accessed on 12 October 2020).

29. Guo, Y.; Shi, D.; Zhang, J.; Mao, S.; Wang, L.; Zhang, W.; Zhang, Z.; Jin, L.; Yang, B.; Ye, L.; et al. The Hemoglobin, Albumin, Lymphocyte, and Platelet (HALP) Score is a Novel Significant Prognostic Factor for Patients with Metastatic Prostate Cancer Undergoing Cytoreductive Radical Prostatectomy. J. Cancer 2019, 10, 81–91. [CrossRef]

30. Fan, L.; Wang, R.; Chi, C.; Cai, W.; Zhang, Y.; Qian, H.; Shao, X.; Wang, Y.; Xu, F.; Pan, J.; et al. Systemic immune-inflammation index predicts the combined clinical outcome after sequential therapy with abiraterone and docetaxel for metastatic castration-resistant prostate cancer patients. Prostate 2018, 78, 250–256. [CrossRef]

31. Notario, L.; Piulats, J.M.; Sala, N.; Ferrandiz, U.; González, A.; Etxáñiz, O.; Heras, L.; Buisan, O.; Del Carpio, L.; Álvarez, A.; et al. 667P Impact of pretreatment neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) on overall survival (OS) in patients (p) with metastatic castration-sensitive prostate cancer (mCSPC) treated with docetaxel (D) plus androgen-deprivation therapy (ADT). Ann. Oncol. 2020, 31, S537. [CrossRef]

32. Guan, Y.; Xiong, H.; Feng, Y.; Liao, G.; Tong, T.; Pang, J. Revealing the prognostic landscape of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in metastatic castration-resistant prostate cancer patients treated with abiraterone or enzalutamide: A meta-analysis. Prostate Cancer Prostatic Dis. 2020, 23, 220–231. [CrossRef]

33. Lozano Martínez, A.J.; Moreno Cano, R.; Escobar Páramo, S.; Salguero Aguilar, R.; Gonzalez Billalabeitia, E.; García Fernández, R.; De La Fuente Muñoz, I.; Romero Borque, A.; Forras Martínez, M.; Lopez Soler, F.; et al. Platelet-lymphocyte and neutrophil-lymphocyte ratios are prognostic but not predictive of response to abiraterone acetate in metastatic castration-resistant prostate cancer. Clin. Transl. Oncol. 2017, 19, 1531–1536. [CrossRef]

34. Soeters, P.B.; Wolfe, R.R.; Shenkin, A. Hypoalbuminemia: Pathogenesis and Clinical Significance. Ipn. J. Parenter Enter. Nutr. 2019, 43, 181–193. [CrossRef]

35. Mori, K.; Janisch, F.; Mostafaei, H.; Lysenko, I.; Karakiewicz, P.I.; Enkenev, D.V.; Briganti, A.; Kimura, S.; Egawa, S.; Shariat, S.F. Prognostic Value of Hemoglobin in Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Meta-analysis. Jpn. J. Parenter Enter. Nutr. 2020, 18, e402–e409. [CrossRef] [PubMed]

36. Beer, T.M.; Tangen, C.M.; Bland, L.B.; Thompson, I.M.; Crawford, E.D. Prognostic value of anemia in newly diagnosed metastatic prostate cancer: A multivariate analysis of southwest oncology group study 8894. J. Urol. 2004, 172, 2213–2217. [CrossRef] [PubMed]
37. Green, S.L.; Giaccia, A.J. Tumor hypoxia and the cell cycle: Implications for malignant progression and response to therapy. Cancer J. Sci. Am. 1998, 4, 218–223. [PubMed]

38. Harrison, L.; Blackwell, K. Hypoxia and anemia: Factors in decreased sensitivity to radiation therapy and chemotherapy? Oncologist 2004, 9 (Suppl. 5) (Suppl. 5), 31–40. [CrossRef]

39. Semenza, G. Signal transduction to hypoxia-inducible factor 1. Biochem. Pharm. 2002, 64, 993–998. [CrossRef]

40. Petrylak, D.P.; Ankerst, D.P.; Jiang, C.S.; Tangen, C.M.; Hussain, M.H.; Lara, P.N., Jr.; Jones, J.A.; Taplin, M.E.; Burch, P.A.; Kohli, M.; et al. Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. J. Natl. Cancer Inst. 2006, 98, 516–521. [CrossRef] [PubMed]

41. Matsubara, N.; Chi, K.N.; Özgüroğlu, M.; Rodriguez-Antolin, A.; Feyerabend, S.; Fein, L.; Alekseev, B.Y.; Sulur, G.; Protheroe, A.; Li, S.; et al. Correlation of Prostate-specific Antigen Kinetics with Overall Survival and Radiological Progression-free Survival in Metastatic Castration-sensitive Prostate Cancer Treated with Abiraterone Acetate plus Prednisone or Placebos Added to Androgen Deprivation Therapy: Post Hoc Analysis of Phase 3 LATITUDE Study. Eur. Urol. 2020, 77, 494–500. [CrossRef]

42. Beer, T.M.; Miller, K.; Tombal, B.; Cella, D.; Phung, D.; Holmstrom, S.; Ivanescu, C.; Skaltsa, K.; Naidoo, S. The association between health-related quality-of-life scores and clinical outcomes in metastatic castration-resistant prostate cancer patients: Exploratory analyses of AFFIRM and PREVAIL studies. Eur. J. Cancer 2017, 87, 21–29. [CrossRef]